KR101833465B1 - 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 - Google Patents

항신경 성장 인자 항체 및 그의 제조방법과 이용방법 Download PDF

Info

Publication number
KR101833465B1
KR101833465B1 KR1020137032545A KR20137032545A KR101833465B1 KR 101833465 B1 KR101833465 B1 KR 101833465B1 KR 1020137032545 A KR1020137032545 A KR 1020137032545A KR 20137032545 A KR20137032545 A KR 20137032545A KR 101833465 B1 KR101833465 B1 KR 101833465B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino acid
antibody
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137032545A
Other languages
English (en)
Korean (ko)
Other versions
KR20140041532A (ko
Inventor
데이비드 기어링
Original Assignee
넥스베트 오스트레일리아 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥스베트 오스트레일리아 피티와이 리미티드 filed Critical 넥스베트 오스트레일리아 피티와이 리미티드
Publication of KR20140041532A publication Critical patent/KR20140041532A/ko
Application granted granted Critical
Publication of KR101833465B1 publication Critical patent/KR101833465B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137032545A 2011-05-06 2012-05-08 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 Active KR101833465B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161483491P 2011-05-06 2011-05-06
US61/483,491 2011-05-06
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051004 WO2012153123A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
KR20140041532A KR20140041532A (ko) 2014-04-04
KR101833465B1 true KR101833465B1 (ko) 2018-02-28

Family

ID=46168541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137032545A Active KR101833465B1 (ko) 2011-05-06 2012-05-08 항신경 성장 인자 항체 및 그의 제조방법과 이용방법

Country Status (14)

Country Link
US (2) US20140170136A1 (enExample)
EP (2) EP3502136A1 (enExample)
JP (2) JP6181043B2 (enExample)
KR (1) KR101833465B1 (enExample)
CN (1) CN103764677A (enExample)
AU (1) AU2012252153B2 (enExample)
BR (1) BR112013028652A8 (enExample)
CA (1) CA2834983C (enExample)
ES (1) ES2704007T3 (enExample)
GB (1) GB2504888B (enExample)
MY (1) MY160884A (enExample)
RU (1) RU2640252C2 (enExample)
SG (2) SG194795A1 (enExample)
WO (1) WO2012153123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
EP3201230B1 (en) 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
AU2016268625B2 (en) * 2015-05-22 2022-01-27 Astellas Pharma Inc. Novel anti-human NGF antibody Fab fragment
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
AU2019250128A1 (en) 2018-10-15 2020-04-30 Avent Inc. Compositions, systems, kits, and methods for neural ablation
EP4232096A4 (en) * 2020-10-22 2024-10-09 Scout Bio, Inc. Method of suppressing immune response to vector-delivered therapeutic protein
CA3218542A1 (en) 2021-05-12 2022-11-17 Hua Ying Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
EP4396237A4 (en) 2021-08-31 2025-11-19 Scout Bio Inc Antigen-binding molecules and their uses
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
PL1732949T3 (pl) * 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US8337842B2 (en) * 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
CA2791866A1 (en) * 2010-03-04 2011-09-09 Vet Therapeutics, Inc. Monoclonal antibodies directed to cd52
EP2542262A4 (en) * 2010-03-04 2014-02-26 Vet Therapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST CD20
JP6121903B2 (ja) * 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2010128398A1 (en) 2009-05-04 2010-11-11 Pangenetics 110 B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Immunol. 43(8): 1243-1257(2005.08.22. 인터넷 공지)
Vet. Immunol. Immunopathol. 110(3-4): 363-367(2006.02.09.)

Also Published As

Publication number Publication date
KR20140041532A (ko) 2014-04-04
EP3502136A1 (en) 2019-06-26
US20140170136A1 (en) 2014-06-19
JP2014519318A (ja) 2014-08-14
RU2640252C2 (ru) 2017-12-27
EP2705056A1 (en) 2014-03-12
ES2704007T3 (es) 2019-03-13
GB201320050D0 (en) 2013-12-25
JP6526089B2 (ja) 2019-06-05
JP6181043B2 (ja) 2017-08-16
NZ617448A (en) 2015-01-30
US20190276525A1 (en) 2019-09-12
CA2834983A1 (en) 2012-11-15
AU2012252153A8 (en) 2013-12-19
WO2012153123A1 (en) 2012-11-15
GB2504888A (en) 2014-02-12
MY160884A (en) 2017-03-31
CN103764677A (zh) 2014-04-30
RU2013154307A (ru) 2015-06-20
EP2705056B1 (en) 2018-11-14
SG194795A1 (en) 2013-12-30
AU2012252153A1 (en) 2013-11-14
JP2017123870A (ja) 2017-07-20
BR112013028652A8 (pt) 2017-12-26
GB2504888B (en) 2016-02-03
BR112013028652A2 (pt) 2016-11-29
AU2012252153B2 (en) 2016-07-07
SG10201500957QA (en) 2015-04-29
CA2834983C (en) 2020-11-17

Similar Documents

Publication Publication Date Title
KR101833465B1 (ko) 항신경 성장 인자 항체 및 그의 제조방법과 이용방법
KR101783398B1 (ko) 항신경성 성장인자 항체 및 그의 제조방법과 이용방법
KR101783929B1 (ko) 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
CA2835094C (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
US20140294815A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
EP4026845A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131206

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160216

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20160216

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160824

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161123

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160615

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160913

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160216

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170601

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20171010

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170502

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170407

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160913

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160216

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240102

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 8

End annual number: 8